ArticleDiagnostics (Basel, Switzerland)2021
The Primacy of High B-Value 3T-DWI Radiomics in the Prediction of Clinically Significant Prostate Cancer.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Diagnostic performance of magnetic resonance imaging-based radiomics for detecting prostate cancer: A systematic review and meta-analysis.World journal of radiology · 2026Article
- Characterization of complex renal cysts in hereditary leiomyomatosis and renal cell cancerUsing magnetic resonance based qualitative features.Abdominal radiology (New York) · 2026Article
- Multicenter Study Suggests Unsupervised Learning Derived From MRI Identifies Prognostic Subgroups in Prostate Cancer Patients After Prostatectomy.Radiology research and practice · 2026Article
- Toward a Refined PI-RADS: The Feasibility and Limitations of More Informative Metrics in Reviewing MRI Scans.Journal of magnetic resonance imaging : JMRI · 2025Review
- Radiomic Pipelines for Prostate Cancer in External Beam Radiation Therapy: A Review of Methods and Future Directions.Journal of clinical medicine · 2024Review
- The Effectiveness of an Adaptive Method to Analyse the Transition between Tumour and Peritumour for Answering Two Clinical Questions in Cancer Imaging.Sensors (Basel, Switzerland) · 2024Article
- Letter to the Editor on "Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review".Insights into imaging · 2023Article
- Review
- Multiparametric MRI radiomics in prostate cancer for predicting Ki-67 expression and Gleason score: a multicenter retrospective study.Discover oncology · 2023Article
- Article
- Radiomic Features from Post-OperativeJournal of clinical medicine · 2023Article
- Article
- Article
- Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review.Insights into imaging · 2022Review
- Measuring the bias of incorrect application of feature selection when using cross-validation in radiomics.Insights into imaging · 2021Article
- Radiomics for Everyone: A New Tool Simplifies Creating Parametric Maps for the Visualization and Quantification of Radiomics Features.Tomography (Ann Arbor, Mich.) · 2021Article
- Radiomics in prostate cancer: an up-to-date review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting clinically significant prostate cancer (csPCa) is crucial in PCa management. 3T-magnetic resonance (MR) systems may have a novel role in quantitative imaging and early csPCa prediction, accordingly. In this study, we develop a radiomic model for predicting csPCa based solely on native b2000 diffusion weighted imaging (DWI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.